FDA Grants Orphan Drug Designation to vTv's HPPD for Sickle Cell Disease
VTVT sits 59% above its 52-week low of $19.5 on light trading volume (0.4× avg).
Summary
The FDA granted Orphan Drug Designation to HPPD, vTv's oral Nrf2/Bach1 modulator, for sickle cell disease. This is a meaningful regulatory milestone for a secondary pipeline asset, providing seven years of market exclusivity upon approval, tax credits, and fee waivers. The designation supports partnering discussions for HPPD while the company focuses on its lead T1D candidate cadisegliatin. Preclinical data showed HPPD increased fetal hemoglobin and reduced sickling in a mouse model. The company's market cap is modest, so this designation could attract partnership interest and validate the program's potential.
At the time of this announcement, VTVT was trading at $31.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.6M. The 52-week trading range was $19.50 to $44.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.